Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.57 USD | +0.78% | +9.36% | -19.18% |
Jun. 04 | Lumos Pharma, Inc. Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024 | CI |
May. 15 | Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.18% | 20.7M | |
+47.77% | 56.87B | |
+37.15% | 39.72B | |
-6.04% | 39.27B | |
-6.90% | 28.73B | |
+13.68% | 26.21B | |
-16.21% | 19.79B | |
+31.22% | 12.28B | |
+28.21% | 12.23B | |
+0.10% | 12.12B |
- Stock Market
- Equities
- LUMO Stock
- News Lumos Pharma, Inc.
- Lumos Pharma Says New Data Shows LUM-201 Restored Growth Hormone Secretion to Similar Levels in Normally Growing Children